Related Experiment Video
Updated: Jun 22, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Relative efficacies: antimalarials to abatacept - the choice is ours
1University of Alberta, 562 Heritage Medical Research Centre, Edmonton, Alberta T6G 2S2, Canada. asr@gpu.srv.ualberta.ca
The Journal of Rheumatology. Supplement
|June 11, 2009
Summary
Early rheumatoid arthritis (RA) treatment is crucial. Combination therapies and newer biologic agents, including cytokine inhibitors, offer improved outcomes for RA patients, especially those unresponsive to initial treatments.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) necessitates prompt diagnosis and intervention to prevent joint damage and functional decline.
- Conventional disease-modifying antirheumatic drugs (DMARDs) show comparable efficacy in monotherapy for radiological and clinical results.
- Refractory RA cases often require advanced therapeutic strategies beyond monotherapy.
Purpose of the Study:
- To review the efficacy of various treatment strategies for rheumatoid arthritis.
- To highlight the role of combination therapies and novel biologic agents in managing RA.
- To provide an overview of current treatment options for RA patients.
Main Methods:
- Literature review of studies on rheumatoid arthritis treatments.
- Analysis of clinical trial data on monotherapy, combination therapy, and biologic agents.
- Synthesis of evidence regarding radiological and clinical outcomes in RA management.
Main Results:
- DMARD monotherapies exhibit similar efficacy in treating RA.
- Combination therapies improve outcomes for patients with inadequate response to monotherapy.
- Cytokine inhibitors and newer biologic therapies offer expanded treatment options for RA.
Conclusions:
- Early RA management is key to mitigating disease progression and preserving function.
- Combination therapies and biologics represent significant advancements in RA treatment.
- A range of effective therapeutic strategies are available for RA patients, with ongoing development of novel agents.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:41Affinity and Avidity
Overview